← Back to Search

Anti-metabolites

mEPIC for Peritoneal Cancer

Phase 2
Recruiting
Led By Mikael Soucisse, MD, FRCSC
Research Sponsored by Ciusss de L'Est de l'Île de Montréal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 weeks (assessed during the hospitalization following the participant's surgery).
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a modified EPIC to maximize therapeutic benefit & limit logistical issues of standard EPIC protocol.

Who is the study for?
Adults with peritoneal tumors from appendiceal or colorectal cancer, who are in good health and have a low ECOG score (0-1), indicating they can perform daily activities without significant restrictions. They must have completed necessary imaging studies, possibly received neoadjuvant therapy, and be able to undergo surgery followed by mEPIC. Exclusions include allergies to Fluorouracil, other cancers, conditions preventing IP therapy, pregnancy, hemodynamic/respiratory compromise post-surgery.
What is being tested?
The trial is testing the feasibility of a modified chemotherapy regimen called mEPIC after cytoreductive surgery and HIPEC for patients with peritoneal carcinomatosis from colorectal or appendicular tumors. It aims to simplify treatment by reducing it to two days using fluorouracil bolus plus infusion based on De Gramont regimen.
What are the potential side effects?
Potential side effects may include those commonly associated with chemotherapy such as nausea, vomiting, fatigue, risk of infection due to lowered blood counts (neutropenia), potential kidney or liver function issues. Specific reactions related to Fluorouracil could also occur.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 weeks (assessed during the hospitalization following the participant's surgery).
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 weeks (assessed during the hospitalization following the participant's surgery). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility of mEPIC
Secondary study objectives
Safety of mEPIC
Satisfaction of care team

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: mEPICExperimental Treatment1 Intervention
Adults (male and female) with a diagnosis of appendicular or colorectal cancer with peritoneal carcinomatosis will undergo mEPIC on post-operative days 1 and 2 following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Find a Location

Who is running the clinical trial?

Maisonneuve-Rosemont HospitalOTHER
101 Previous Clinical Trials
38,302 Total Patients Enrolled
Ciusss de L'Est de l'Île de MontréalLead Sponsor
78 Previous Clinical Trials
6,390 Total Patients Enrolled
Mikael Soucisse, MD, FRCSCPrincipal InvestigatorCIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont

Media Library

Modified early post-operative intraperitoneal chemotherapy (mEPIC) (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT05913674 — Phase 2
Appendiceal Neoplasm Research Study Groups: mEPIC
Appendiceal Neoplasm Clinical Trial 2023: Modified early post-operative intraperitoneal chemotherapy (mEPIC) Highlights & Side Effects. Trial Name: NCT05913674 — Phase 2
Modified early post-operative intraperitoneal chemotherapy (mEPIC) (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05913674 — Phase 2
~17 spots leftby Jan 2026